300 related articles for article (PubMed ID: 27067983)
1. Update of thrombosis in multiple myeloma.
Leebeek FW
Thromb Res; 2016 Apr; 140 Suppl 1():S76-80. PubMed ID: 27067983
[TBL] [Abstract][Full Text] [Related]
2. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Palumbo A; Rajkumar SV; Dimopoulos MA; Richardson PG; San Miguel J; Barlogie B; Harousseau J; Zonder JA; Cavo M; Zangari M; Attal M; Belch A; Knop S; Joshua D; Sezer O; Ludwig H; Vesole D; Bladé J; Kyle R; Westin J; Weber D; Bringhen S; Niesvizky R; Waage A; von Lilienfeld-Toal M; Lonial S; Morgan GJ; Orlowski RZ; Shimizu K; Anderson KC; Boccadoro M; Durie BG; Sonneveld P; Hussein MA;
Leukemia; 2008 Feb; 22(2):414-23. PubMed ID: 18094721
[TBL] [Abstract][Full Text] [Related]
3. Risk of thrombosis with lenalidomide and its prevention with aspirin.
Hirsh J
Chest; 2007 Jan; 131(1):275-7. PubMed ID: 17218586
[TBL] [Abstract][Full Text] [Related]
4. Thromboembolism with immunomodulatory agents in the treatment of multiple myeloma.
Singh A; Gajra A
Cardiovasc Hematol Agents Med Chem; 2011 Jan; 9(1):7-13. PubMed ID: 20874693
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma.
Galli M; Elice F; Crippa C; Comotti B; Rodeghiero F; Barbui T
Haematologica; 2004 Sep; 89(9):1141-2. PubMed ID: 15377478
[TBL] [Abstract][Full Text] [Related]
6. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
Zamagni E; Brioli A; Tacchetti P; Zannetti B; Pantani L; Cavo M
Semin Thromb Hemost; 2011 Apr; 37(3):209-19. PubMed ID: 21455855
[TBL] [Abstract][Full Text] [Related]
7. Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital.
Alexander M; Teoh KC; Lingaratnam S; Kirsa S; Mellor JD
Asia Pac J Clin Oncol; 2013 Jun; 9(2):169-75. PubMed ID: 22998589
[TBL] [Abstract][Full Text] [Related]
8. [Multiple myeloma and venous thrombosis. Which thromboprophylaxis should be given?].
de Moreuil C; Ianotto JC; Eveillard JR; Carrier M; Delluc A
Rev Med Interne; 2016 Jul; 37(7):473-9. PubMed ID: 26833146
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma.
Niesvizky R; Martínez-Baños D; Jalbrzikowski J; Christos P; Furst J; De Sancho M; Mark T; Pearse R; Mazumdar M; Zafar F; Pekle K; Leonard J; Jayabalan D; Coleman M
Leuk Lymphoma; 2007 Dec; 48(12):2330-7. PubMed ID: 18067007
[TBL] [Abstract][Full Text] [Related]
10. Thrombosis in multiple myeloma.
Zangari M; Elice F; Fink L; Tricot G
Expert Rev Anticancer Ther; 2007 Mar; 7(3):307-15. PubMed ID: 17338651
[TBL] [Abstract][Full Text] [Related]
11. Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review.
Al-Ani F; Bermejo JM; Mateos MV; Louzada M
Thromb Res; 2016 May; 141():84-90. PubMed ID: 26986753
[TBL] [Abstract][Full Text] [Related]
12. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Larocca A; Cavallo F; Bringhen S; Di Raimondo F; Falanga A; Evangelista A; Cavalli M; Stanevsky A; Corradini P; Pezzatti S; Patriarca F; Cavo M; Peccatori J; Catalano L; Carella AM; Cafro AM; Siniscalchi A; Crippa C; Petrucci MT; Yehuda DB; Beggiato E; Di Toritto TC; Boccadoro M; Nagler A; Palumbo A
Blood; 2012 Jan; 119(4):933-9; quiz 1093. PubMed ID: 21835953
[TBL] [Abstract][Full Text] [Related]
13. Does the choice of thrombotic prophylactic drug depend on the known risk factors of patients with multiple myeloma in clinical practice?
Chalayer E; Chapelle C; Leleu X; Elalamy I; Laporte S; Tardy B
Thromb Res; 2016 Jul; 143():101-2. PubMed ID: 27208979
[No Abstract] [Full Text] [Related]
14. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis.
Zonder JA; Barlogie B; Durie BG; McCoy J; Crowley J; Hussein MA
Blood; 2006 Jul; 108(1):403; author reply 404. PubMed ID: 16790586
[No Abstract] [Full Text] [Related]
15. [Thromboprophylaxis in patients with multiply myeloma who receives chemotherapy with thalidomide].
Novosad OI; Kriachok IA; Kadnikova TV; Filonenko KS; Tytorenko IB; Martynchyk AV; Aleksyk OM; Gusachenko IuO; Filonenko IA
Lik Sprava; 2011; (3-4):44-50. PubMed ID: 22416363
[TBL] [Abstract][Full Text] [Related]
16. [Thrombotic complications following the treatment of multiple myeloma with new agents].
Rupa-Matysek J; Gil L; Komarnicki M
Pol Merkur Lekarski; 2011 Dec; 31(186):372-7. PubMed ID: 22239010
[TBL] [Abstract][Full Text] [Related]
17. Thrombosis in multiple myeloma.
Kristinsson SY
Hematology Am Soc Hematol Educ Program; 2010; 2010():437-44. PubMed ID: 21239832
[TBL] [Abstract][Full Text] [Related]
18. A review of the venous thrombotic issues associated with multiple myeloma.
Fotiou D; Gerotziafas G; Kastritis E; Dimopoulos MA; Terpos E
Expert Rev Hematol; 2016 Jul; 9(7):695-706. PubMed ID: 27232265
[TBL] [Abstract][Full Text] [Related]
19. Anticoagulation regimens for thalidomide and lenalidomide.
Zangari M
Clin Adv Hematol Oncol; 2006 Sep; 4(9):658-9. PubMed ID: 17099621
[No Abstract] [Full Text] [Related]
20. Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens.
Bagratuni T; Kastritis E; Politou M; Roussou M; Kostouros E; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Kanelias N; Terpos E; Dimopoulos MA
Am J Hematol; 2013 Sep; 88(9):765-70. PubMed ID: 23757261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
